BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 9818464)

  • 1. [Interferon alpha--the drug of choice for patients with chronic myeloid leukemia].
    Klamová H; Vítek A; Michalová K; Brezinová J; Moravcová J; Jelínek J; Cermák J
    Cas Lek Cesk; 1998 Sep; 137(18):552-6. PubMed ID: 9818464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
    Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
    Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
    Nese M; de Bellis R; Urtiarte R; Di Landro J
    Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interferon-alpha in the treatment of patients with chronic myeloid leukemia].
    Faber E; Jarosová M; Divoký V; Luhový M; Komenda S; Sulovská I; Hubácek J; Slezák P; Papajik T; Raida L; Heczko M; Indrák K
    Vnitr Lek; 1997 Jan; 43(1):13-7. PubMed ID: 9221559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.
    Peñarrubia MJ; Odriozola J; González C; Massagué I; Miguel A; González San Miguel JD; Pérez Encinas M; Lavilla E; Giraldo MP; Casado LF; Ferrer S; Steegmann JL;
    Ann Hematol; 2003 Dec; 82(12):750-8. PubMed ID: 14517691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic myeloid leukemia].
    Hehlmann R
    Ther Umsch; 1996 Feb; 53(2):82-7. PubMed ID: 8629268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular biology follow-up of interferon therapy in patients with chronic myeloid leukemia].
    Iványi JL; Marton E; Kereskai L; Kiss Z; Pajor L
    Orv Hetil; 2000 Nov; 141(47):2527-33. PubMed ID: 11143285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alpha in the treatment of chronic myelogenous leukemia.
    Robak T
    Arch Immunol Ther Exp (Warsz); 1998; 46(6):347-53. PubMed ID: 9883313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M
    Semin Oncol; 1994 Dec; 21(6 Suppl 14):8-13. PubMed ID: 7992099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
    Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
    Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa].
    Tóthová E; Stecová N; Kafková A; Fricová M; Svorcová E
    Vnitr Lek; 2002 May; 48(5):380-3. PubMed ID: 12061203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative efficiency of conventional myelosuppressive chemotherapy and therapy including interferon alpha in patients with chronic myeloid leukemia].
    Volkova SA; Prytkova MV; Borovkov NN
    Klin Med (Mosk); 2004; 82(3):45-50. PubMed ID: 15114775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
    Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
    Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alpha-interferons in the treatment of patients with chronic myeloid leukemia].
    Abdulkadyrov KM; Udal'eva VIu; Rukavitsyn OA; Bessmel'tsev SS
    Vopr Onkol; 1999; 45(4):387-92. PubMed ID: 10532097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment with lymphoblastoid alpha interferon in patients with chronic myeloid leukemia refractory to recombinant interferon alpha 2].
    Steegmann JL; Granados E; Vázquez L; de la Cámara R; Peñarrubia MJ; Fernández-Contreras E; Quiroga JA; Fernández Rañada JM
    Sangre (Barc); 1998 Oct; 43(5):443-6. PubMed ID: 9868341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.